Art. -Nr.: HY-50940

AT7519

(Synonyms: AT7519M)

18 Cited Publications

Kundenbewertung

Based on 18 publication(s) in Google Scholar

AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.69%
CAS. Nr.: 844442-38-2
Formel: C₁₆H₁₇Cl₂N₅O₂
Molecular Weight:382.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

AT7519 Chemical Structure

CAS. Nr.: 844442-38-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (18)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

IC₅₀ & Target^[2]

CDK9/Cyclin T

10 nM (IC₅₀)

CDK5/p35

13 nM (IC₅₀)

cdk2/cyclin A

47 nM (IC₅₀)

Cdk4/cyclin D1

100 nM (IC₅₀)

cdk6/cyclin D3

170 nM (IC₅₀)

Cdk1/cyclin B

210 nM (IC₅₀)

CDK7/Cyclin H/MAT1

2400 nM (IC₅₀)

GSK3β

89 nM (IC₅₀)

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2058	IC₅₀	0.166 μM Compound: AT7519	Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay	[PMID: 33611192]
A2780	IC₅₀	350 nM Compound: 33	Antiproliferative activity against human A2780 cells assessed as cell viability after 72 hrs by alamar blue assay Antiproliferative activity against human A2780 cells assessed as cell viability after 72 hrs by alamar blue assay	[PMID: 18656911]
ASPC1	IC₅₀	533 nM Compound: AT7519	Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
BXPC-3	IC₅₀	640 nM Compound: AT7519	Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
HCT-116	IC₅₀	0.082 μM Compound: 33	Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by alamar blue assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 72 hrs by alamar blue assay	[PMID: 18656911]
HCT-116	IC₅₀	80 nM Compound: AT7519	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by Alamar blue assay	[PMID: 26115571]
HCT-116	IC₅₀	132 nM Compound: AT7519	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by cell titer glo-based luminescence assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by cell titer glo-based luminescence assay	[PMID: 31175010]
HL-60	IC₅₀	2.33 μM Compound: AT7519	Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HL-60 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
HL-60	IC₅₀	134.77 nM Compound: AT7519	Antiproliferative activity against human HL-60 cells measured after 1 to 3 days by CCK-8 assay Antiproliferative activity against human HL-60 cells measured after 1 to 3 days by CCK-8 assay	[PMID: 38878515]
Kasumi 1	IC₅₀	1.48 μM Compound: AT7519	Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Kasumi 1 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]
MIA PaCa-2	IC₅₀	411 nM Compound: AT7519	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay	[PMID: 30343954]
MRC5	IC₅₀	980 nM Compound: 33	Antiproliferative activity against human MRC5 cells assessed as cell viability after 72 hrs by alamar blue assay Antiproliferative activity against human MRC5 cells assessed as cell viability after 72 hrs by alamar blue assay	[PMID: 18656911]
MRC5	IC₅₀	>10000 nM Compound: 33	Antiproliferative activity against human MRC5 nonprolifreative cells assessed as cell viability after 72 hrs by alamar blue assay Antiproliferative activity against human MRC5 nonprolifreative cells assessed as cell viability after 72 hrs by alamar blue assay	[PMID: 18656911]
MRC5	IC₅₀	0.425 μM Compound: AT7519	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay	[PMID: 33611192]
MV4-11	IC₅₀	0.391 μM Compound: AT7519	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 96 hrs by Celltiter-Glo luminescent assay	[PMID: 33611192]
MV4-11	IC₅₀	0.12 μM Compound: AT7519; 1	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay	[PMID: 37465296]
PC-3	IC₅₀	0.71 μM Compound: 1; AT-7519	Antiproliferative activity against AR-negative human PC3 cells assessed as reduction in cell viability after 5 days by CCK8 assay Antiproliferative activity against AR-negative human PC3 cells assessed as reduction in cell viability after 5 days by CCK8 assay	[PMID: 31846828]
Sf21	IC₅₀	<10 nM Compound: AT7519	Inhibition of recombinant human full-length C-terminal His6-tagged CDK9/human full-length untagged cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate Inhibition of recombinant human full-length C-terminal His6-tagged CDK9/human full-length untagged cyclin T1 expressed in baculovirus infected Sf21 insect cells using PDKtide as substrate	[PMID: 30543440]
Sf21	IC₅₀	210 nM Compound: AT7519	Inhibition of recombinant full-length human C-terminal His6-tagged CDK1/human full-length N-terminal GST-tagged Cyclin B expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate measured after 2 hrs in presence of gamma[32P] ATP b Inhibition of recombinant full-length human C-terminal His6-tagged CDK1/human full-length N-terminal GST-tagged Cyclin B expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate measured after 2 hrs in presence of gamma[32P] ATP b	[PMID: 30543440]
Sf21	IC₅₀	2400 nM Compound: AT7519	Inhibition of recombinant human C-terminal His6-tagged full length CDK7/untagged recombinant full length human Cyclin H/N-terminal GST-tagged recombinant full length human MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 peptide as subs Inhibition of recombinant human C-terminal His6-tagged full length CDK7/untagged recombinant full length human Cyclin H/N-terminal GST-tagged recombinant full length human MAT1 expressed in baculovirus infected Sf21 insect cells using cdk7 peptide as subs	[PMID: 30543440]
Sf21	IC₅₀	360 nM Compound: AT7519	Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate Inhibition of recombinant human full-length C-terminal His6-tagged CDK3/full-length human N-terminal GST-tagged Cyclin E expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate	[PMID: 30543440]
T-cell	IC₅₀	<100 nM Compound: AT7519	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 19169685]
T-cell	IC₅₀	0.01 μM Compound: 13; AT7519	Inhibition of CDK9/Cyclin T (unknown origin) Inhibition of CDK9/Cyclin T (unknown origin)	[PMID: 35485642]
U-937	IC₅₀	1.15 μM Compound: AT7519	Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human U-937 cells incubated for 72 hrs by CCK8 assay	[PMID: 36736154]

In Vitro

AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC₅₀s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells^[1]. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines^[2]. AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AT7519 inhibits tumor growth in a human MM xenograft mouse model^[1]. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 844442-38-2
Appearance Solid
Molecular Weight 382.24
Formel C₁₆H₁₇Cl₂N₅O₂
Color White to off-white
SMILES

O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl
Synonyms

AT7519M
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (18)

All RT-PCRCell Proliferation/Viability AssayIPWB

Sort by:

Journal Impact Factor

Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Adv Sci (Weinh)

SHMT2 Mediates Small-Molecule-Induced Alleviation of Alzheimer Pathology Via the 5'UTR-dependent ADAM10 Translation Initiation. [Abstract]

2024 Mar;11(11):e2305260. PMID: 38183387

AT7519 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Mar;11(11):e2305260. [Abstract]

Chemical structure of another CDK/GSK inhibitor AT7519 (top), and immunoblots (middle) and quantification (bottom) of ADAM10 in SH‐SY5Y cells treated with AT7519 (1 to 20 µM for 36 h, n = 5)
Cell Rep Med

2026 May 14:102819. PMID: 42140195
EMBO Mol Med

Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice. [Abstract]

2025 Nov 26. PMID: 41299101
Oncogene

D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC. [Abstract]

2023 Nov;42(47):3503-3513. PMID: 37845392

AT7519 purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Nov;42(47):3503-3513. [Abstract]

Western blot analysis of the levels of pGSK3β (S9), GSK3β and EGFR in A549 and PC9 cells treated with AT7519 (0.5 μM, 30 h), DIF-3 (30 μM, 30 h) and D-mannose (25 mM, 24 h) as indicated.
Cell Chem Biol

Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. [Abstract]

2018 Feb 15;25(2):135-142.e5. PMID: 29276047
FEBS J

2026 May 4. PMID: 42080702
FASEB J

CDK9 inhibition activates innate immune response through viral mimicry. [Abstract]

2024 Apr 30;38(8):e23628. PMID: 38661032

AT7519 purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]

RT-qPCR data analysis showing the on-target effect of CDK9 inhibition (500 nM AT7519 for 4 h) on MYC mRNA.

AT7519 purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]

Cell viability was measured using CellTiter-Glo after 4 days of treatment with mTOR inhibitor (everolimus) in the presence or absence of AT7519 (LNCaP and C4-2: 0.5 μM; 22RV1: 2 μM).

AT7519 purchased from MedChemExpress. Usage Cited in: FASEB J. 2024 Apr 30;38(8):e23628. [Abstract]

LNCaP cells were treated with a CDK9 inhibitor (500 nM AT7519) for 4 h, and wheat germ agglutinin (WGA)-lectin pulldown was used to enrich for proteins O-GlcNAcylated in the given conditions. The data are representative of two biological replicates; OGT is used as a positive control andactin as a negative control in the pulldown samples. For clarity, both long- and short- exposure Western blots of MAVS antibody are shown. Densitometry was used to determine the signal intensities.
Sci Rep

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells. [Abstract]

2021 Mar 8;11(1):5374. PMID: 33686114
RNA Biol

Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. [Abstract]

2021 Nov 12;18(sup2):722-729. PMID: 34592899
Glycobiology

O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition. [Abstract]

2022 Aug 18;32(9):751-759. PMID: 35708495
Mol Carcinog

Purvalanol A Exerts Anti-Hepatocellular Carcinoma Activity by Activating the p53 Pathway. [Abstract]

2025 Dec 2. PMID: 41328606
Exp Eye Res

Involvement of aberrant acinar cell proliferation in scopolamine-induced dry eye mice. [Abstract]

2023 Feb:227:109391. PMID: 36696946
PLoS One

Efficacy of NAMPT inhibition in T-cell acute lymphoblastic leukemia. [Abstract]

2025 Jun 17;20(6):e0324443. PMID: 40526635
Dev Biol

Neutrophils facilitate the epicardial regenerative response after zebrafish heart injury. [Abstract]

2024 Apr:508:93-106. PMID: 38286185
SSRN

2026 May 20.
bioRxiv

2025 Nov 17.
bioRxiv

2024 September 07.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (130.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6161 mL

13.0806 mL

26.1613 mL

5 mM

0.5232 mL

2.6161 mL

5.2323 mL

10 mM

0.2616 mL

1.3081 mL

2.6161 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

AT7519's effects on viability of MM cell lines, primary MM cells, and PBMNCs is assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrasodium bromide (MTT) dye absorbance. DNA synthesis is measured by tritiated thymidine uptake (3H-TdR). MM cells (2-3 × 10⁴ cells/well) are incubated in 96-well culture plates with media and different concentrations of AT7519 and/or recombinant IL-6 (10 ng/mL) or IGF-1 (50 ng/mL) for 24 or 48 h at 37°C and 3H-TdR incorporation is measured.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

To evaluate the in vivo anti-MM activity of AT7519, male SCID mice are inoculated subcutaneously with 5×10⁶ MM.1S cells in 100 μL serum-free RPMI 1640 medium. When tumors are measurable, mice are treated intraperitoneally (IP) with vehicle or AT7519 dissolved in saline 0.9%. The first group of 10 mice is treated with 15 mg/kg once a day for five days for 2 weeks, and the second group is treated with 15 mg/kg once a day three times a week for four consecutive weeks. The control group receives the carrier alone at the same schedule. Tumor size is measured every alternate day in 2 dimensions using calipers, and tumor volume is calculated with the formula: V= 0.5 a × b² (a= long diameter of the tumor, b= short diameter of the tumor). Animals are sacrificed when the tumor reaches 2 cm³ or when the tumor is ulcerated. Survival and tumor growth are evaluated from the first day of treatment until death.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36. [Content Brief]

[2]. Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [Content Brief]

[3]. Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6161 mL	13.0806 mL	26.1613 mL	65.4032 mL
	5 mM	0.5232 mL	2.6161 mL	5.2323 mL	13.0806 mL
	10 mM	0.2616 mL	1.3081 mL	2.6161 mL	6.5403 mL
	15 mM	0.1744 mL	0.8720 mL	1.7441 mL	4.3602 mL
	20 mM	0.1308 mL	0.6540 mL	1.3081 mL	3.2702 mL
	25 mM	0.1046 mL	0.5232 mL	1.0465 mL	2.6161 mL
	30 mM	0.0872 mL	0.4360 mL	0.8720 mL	2.1801 mL
	40 mM	0.0654 mL	0.3270 mL	0.6540 mL	1.6351 mL
	50 mM	0.0523 mL	0.2616 mL	0.5232 mL	1.3081 mL
	60 mM	0.0436 mL	0.2180 mL	0.4360 mL	1.0901 mL
	80 mM	0.0327 mL	0.1635 mL	0.3270 mL	0.8175 mL
	100 mM	0.0262 mL	0.1308 mL	0.2616 mL	0.6540 mL

Keywords

AT7519

18 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AT7519

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) AT7519

Alle CDK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (18)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AT7519 Related Classifications

HY-50940 Related Classifications